ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1342	National Cancer Institute	Html	en	Secondhand Smoke and Cancer	A fact sheet that summarizes the studies on the health effects of exposure to environmental (secondhand) tobacco smoke.	safe level 0.379875 passive smoke 0.502001 Human Services 0.468341 nonsmoking adults 0.357216 secondhand tobacco smoke 0.68104 U.S. Department 0.464191 lung cancer 0.378247 Cancer Progress Report 0.355171 burning tobacco product 0.42493 secondhand smoke 0.997055 Environmental Health Hazard 0.364487 Tobacco Control Monograph 0.372592 tobacco smoke 0.693112 U.S. Surgeon General 0.402428 Tobacco Smoke Causes 0.494425 tobacco products 0.362817 nationwide health promotion 0.362703 Environmental Tobacco Smoke—ETS 0.377837 Environmental Protection Agency 0.465583 contain harmful chemicals 0.358856 health effects 0.390654 disease prevention agenda 0.353662 United States 0.418836 National Toxicology Program 0.432935 health promotion 0.395997	U.S. Environmental Protection 0.431643 sudden infant death 0.405056 public places 0.357277 U.S. National Toxicology 0.366163 infant death syndrome 0.405701 heart disease 0.378172 smoking 0.358862 National Cancer Institute 0.4772 smoke cause cancer 0.529335 heart disease deaths 0.35595 Respiratory Health Effects 0.361324 tobacco product 0.437535 secondhand smoke exposure 0.747052 sinus cavity cancer 0.360979 health 0.407857 tobacco smoke cause 0.527224 environmental tobacco smoke 0.625449 Chronic Disease Prevention 0.389 lung cancer deaths 0.360096 Surgeon General 0.4042 Public Health Service 0.390186 involuntary smoke 0.507716 ear infections 0.356303 testing indoor air 0.35347	CLICK HERE
1589	National Cancer Institute	Html	en	Adrenocortical Carcinoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adrenocortical carcinoma.	treatment 0.550891 malignant tumor cells 0.393623 cancer treatment 0.339234 NCI-supported cancer 0.325244 cancer cells 0.380323 Adrenocortical Carcinoma Home 0.328751 adrenal cortex 0.482225 body 0.41124 adrenocortical carcinoma spreads 0.336583 PDQ cancer information 0.400868 adrenal medulla 0.329784 clinical trial search 0.399161 treatment clinical trials 0.346018 affected adrenal gland 0.313913 National Cancer Institute 0.418105 clinical trials 0.816364 adrenal gland 0.62258 High blood pressure 0.300595 Adrenal gland cells 0.329473 normal cells 0.306099 cancer information summary 0.36038 clinical trial 0.576848 Adrenocortical Carcinoma Treatment 0.355819	new treatment 0.426441 nonfunctioning adrenocortical tumor 0.334163 detailed pictures 0.31402 patients 0.305698 adrenocortical carcinoma 0.949806 Recurrent adrenocortical carcinoma 0.379499 adrenocortical carcinoma cells 0.349105 adrenal glands 0.394752 blood 0.322073 nuclear magnetic resonance 0.302225 PDQ summary 0.318647 treatment clinical trial 0.305174 NCI PDQ cancer 0.312561 Treatment Option Overview 0.314325 cancer clinical trials 0.41336 lymph nodes 0.306574 radiation therapy 0.311431 Treatment Editorial Board 0.302427 cancer 0.760261 information 0.413368 standard treatment 0.301619 adrenocortical carcinoma depend 0.345997 positron emission tomography 0.305618	CLICK HERE
1805	National Cancer Institute	Html	es	Tratamiento del cáncer de ano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.	Anal Cancer Trial 0.489207 results from 0.31371 John M 0.347549 with external radiotherapy 0.314904 anal canal 0.794085 combined modality therapy 0.350825 Trial Working Party 0.324488 randomized intergroup study 0.336989 Radiation Therapy Oncology 0.354467 perianal epidermoid cancers 0.314329 Radiat Oncol Biol 0.493627 anal intraepithelial neoplasia 0.3483 Natl Cancer Inst 0.358284 Flam M 0.355801 epidermoid carcinoma 0.391708 patients with 0.3347 radiation therapy 0.487367 preoperative multidisciplinary therapy 0.316168 squamous carcinoma 0.31988 intraepitelial anal ii–iii 0.32888 Krall JM 0.319145 Cancer Trial Working 0.342892 estadio ii 0.314589 Pajak TF 0.321788 Therapy Oncology Group 0.342392	with anal squamous 0.330697 anal carcinoma 0.555894 patients with carcinoma 0.314283 adjuvant combined modality 0.322897 combined with chemotherapy 0.336207 Oncology Group study 0.357157 Cancer Research 0.342768 therapy combined with 0.337029 Definitive irradiation 0.321135 randomised ukcccr anal 0.326366 interim report 0.31903 versus radiotherapy 0.314135 Clin Oncol 0.342577 Sischy B 0.347382 Oncol Biol Phys 0.504444 UK Co-ordinating Committee 0.321139 anal cancer 0.987825 definitive nonsurgical treatment 0.344247 optimal radiation 0.320998 advanced anal canal 0.329424 UKCCCR Anal Cancer 0.435954 implantation combined with 0.313892 anal canal carcinoma 0.398943 Doggett RL 0.318887	CLICK HERE
1831	National Cancer Institute	Html	es	Tratamiento del cáncer de vulva (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vulva.	Obstet Gynecol 0.804289 Lippincott Williams 0.202983 if proper radiation 0.203498 Bundy BN 0.397552 American Cancer Society 0.185854 vulvar carcinoma relative 0.190758 recurrent vulvar carcinoma 0.181549 vulvar squamous 0.170463 Primary groin irradiation 0.19228 vulvar carcinoma 0.421111 vulva maligno 0.200949 Radiat Oncol Biol 0.676441 DeVita VT Jr 0.292636 ISSVD Vulvar Oncology 0.241137 Obstet Gynecol Surv 0.191408 invasive vulvar carcinoma 0.181789 oncology group study 0.572234 Vulvar Oncology Subcommittee 0.241135 Thomas GM 0.191015 ganglios centinela 0.614725 Gynecol Oncol 0.971056 Rosenberg SA 0.195184 Database Syst Rev 0.701338 gynecologic oncology group 0.768104 Lawrence TS 0.197994	vulva with positive 0.200833 vulva treated with 0.19129 Markman MA 0.205496 vulva with emphasis 0.35831 Groin dissection versus 0.18662 vulva with 0.53285 vulval intraepithelial neoplasia 0.258055 Sedlis A 0.219223 equivalent to lymphadenectomy 0.170809 Eifel PJ 0.266136 Berek JS 0.206241 9th ed 0.206706 Clin Oncol 0.161496 vulvar intraepithelial neoplasia 0.93471 primary groin 0.238863 Oncol Biol Phys 0.700325 Radiation therapy 0.257312 Velden J 0.269821 groin irradiation versus 0.187219 Radical radiotherapy 0.168465 intraepithelial neoplasia with 0.201641 irradiation versus primary 0.185741 proper radiation technique 0.204024 intraepithelial neoplasia iii 0.18929	CLICK HERE
1864	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	mutación jak2 0.0546285 Campbell PJ 0.0405614 primary myelofibrosis 0.131535 polycythaemia vera 0.093088 Health Organization classification 0.0291993 have myelofibrosis with 0.0314259 Mesa RA 0.119444 or calr mutation 0.036061 with nonmutated jak2 0.0536842 myeloproliferative neoplasms 0.261769 thousand patients with 0.0269901 with polycythemia vera 0.195275 Vera Study Group 0.0949279 leucemia mielógena 0.0351738 polycythemia vera with 0.109106 stem cell transplantation 0.0588703 transfusion-dependent patients with 0.0283801 patients with philadelphia 0.0316383 myeloproliferative disorders 0.146587 vera with jak2v617f 0.038469 calr mutation 0.0482163 Leuk Lymphoma 0.0369689 with essential thrombocythemia 0.0866875 patients with 0.725855 Verstovsek S 0.0388869	essential thrombocythemia 0.44083 patients with primary 0.0790517 metaplasia with myelofibrosis 0.0416952 with myeloid metaplasia 0.913374 essential thrombocythaemia 0.0355199 CALR mutation status 0.0373736 Organization classification system 0.0297845 with primary myelofibrosis 0.0630012 jak2 or calr 0.0410501 sudores nocturnos 0.0340921 leucemia aguda 0.0337979 patients with myelofibrosis 0.203296 vera with recombinant 0.0414353 Thiele J 0.0617064 patients with polycythemia 0.16042 myelofibrosis with 0.580226 polycythemia vera 0.713605 Tefferi A 0.30746 thrombocythemia with substantially 0.0550099 Polycythemia Vera Study 0.106061 with substantially different 0.0495287 Clin Oncol 0.190573 neoplasms with nonmutated 0.0489374 essential thrombocythemia with 0.102281	CLICK HERE
3425	National Cancer Institute	Html	es	Estrés psicológico y el cáncer	Hoja informativa que describe los efectos del estrés en el cuerpo, los resultados de investigaciones sobre la relación entre el estrés y el cáncer e información sobre cómo superar el estrés.	Sood AK 0.430056 care standards from 0.338514 determinadas hormonas 0.324248 Antoni MH 0.367904 tumor biology 0.324968 metastatic switch 0.319814 Dahmoush L 0.320856 psychological distress 0.325611 DeGeest K 0.320069 Dy SM 0.323303 Discovery Medicine 0.320658 estrés resultante 0.422988 biobehavioral signaling pathways 0.342266 peor calidad 0.321062 immune system 0.320953 McDonald PG 0.320742 Host factors 0.321766 Supportive Oncology 0.337163 Cox BF 0.320273 Psychological stress 0.329279 elevated tumor 0.324862 print march 0.323271	biobehavioral perspective 0.328519 familiar cercano 0.324843 tejidos adiposos mamarios 0.340834 sympathetic nervous system 0.335164 Lutgendorf SK 0.581508 Martinez KA 0.323343 ratones portadores 0.329629 PubMed Abstract 0.950792 killer cell activity 0.340076 carcinoma patients 0.32286 meta-analytic study 0.320949 Social isolation 0.322911 Lei X 0.320438 Priceman SJ 0.320893 peores resultados 0.32033 Clinical Oncology 0.442906 primary breast 0.321519 Segerstrom SC 0.320085 Psychological Bulletin 0.326317 largo tiempo 0.321876 bloqueadores beta 0.426953	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
15907	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	siguientes teorías 0.410914 suficiente información 0.405414 Centro Nacional 0.412476 Phaseolus lunatus 0.410368 New Hampshire Avenue 0.408624 Drug Administration 0.405353 NCI Best Case 0.416678 fase i 0.407749 datos bibliográficos pubmed 0.409348 largo plazo 0.408034 siguientes preguntas 0.406283 vitamina b17 0.411219 cuáles tipos 0.408099 vitamina c 0.408062 vitamina a 0.409071 siguientes riesgos 0.407854 seguro médico 0.405074 Instituto Nacional 0.512438	Salud Complementaria 0.418716 Visuals Online 0.406445 siguientes resultados 0.443523 complementarias revisa 0.408971 Physician Data Query 0.437362 siguientes causas 0.409284 Estados Unidos 0.980672 enzimas pancreáticas 0.42962 Corte Suprema 0.408891 libre uso 0.407165 determinadas frutas 0.407416 página manejo 0.406016 ¿El tratamiento 0.415719 ¿Los beneficios 0.405473 juntos cam 0.405199 Series Program 0.405225 medicina complementaria 0.651404	CLICK HERE
16717	National Cancer Institute	Html	en	Cancer Clinical Trials at the National Institutes of Health Clinical Center	Information about cancer clinical trials at the NIH Clinical Center in Bethesda, Maryland.	cancer treatment 0.534356 better understanding 0.369317 clinical program 0.414778 eligibility criteria 0.37194 health insurance 0.371915 novel cancer treatment 0.457878 International patients 0.371646 health care provider 0.502194 clinical trial experience 0.462664 clinical teams 0.407146 NIH physicians 0.420773 Patients page 0.377331 NCI clinic 0.401655 open trials 0.377021 in-house cancer center 0.477433 Patient Self-Referral Form 0.427003 unique hospital 0.366285 clinical trials 0.623234 treatment services 0.380122 health care providers 0.57596 approach fosters interaction 0.418119 National Institutes 0.375152 clinical trial 0.527278 contact information 0.370247 CCR clinical trials 0.482065	patients 0.409802 cancer patients 0.399962 standard treatment options 0.440025 trial’s eligibility 0.38116 related research 0.378808 patient care units 0.440886 United States 0.412623 largest hospital 0.37768 cancer research 0.528759 NIH Clinical Center 0.949828 National Cancer Institute 0.460111 NCI research team 0.453825 Clinical Research Referral 0.467688 Developmental Therapeutics Clinic 0.698646 advanced cancer 0.386466 trial information 0.38805 new treatments 0.372193 NCI principal investigator 0.437174 patient treatment plans 0.430619 compassionate doctors 0.368527 care specialists 0.389607 medical care 0.431584 scientific resources 0.368533 trial summary 0.38584	CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE